Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Filings · News reference
Frenome Files Prospectus Related To The Offer And Sale From Time To Time By The Selling Securityholders Of Up To 75,188,742 Shares Of Common Stock
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Watching Freenome; Traders Circulate Unconfirmed Analyst Comments Suggesting Carelon Healthcare Services (ELV) Just Updated Clinical Guideline Reimbursements To Include Freenome’s SimpleScreen
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq falls 0.1%. Gap Inc shares rise 15.2% on strong earnings and raised guidance. Other big gainers include Elastic NV, Solstice Advanced Materials Inc, and Pagerduty Inc.
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $21.